Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma

Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing...

Descripción completa

Detalles Bibliográficos
Autores principales: Musselman, Kelsey, Glynn, Shannon, Mosquera, Juan Miguel, Elemento, Olivier, Sboner, Andrea, Beltran, Himisha, Holcomb, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411491/
https://www.ncbi.nlm.nih.gov/pubmed/30906838
http://dx.doi.org/10.1016/j.gore.2019.01.013
_version_ 1783402393310855168
author Musselman, Kelsey
Glynn, Shannon
Mosquera, Juan Miguel
Elemento, Olivier
Sboner, Andrea
Beltran, Himisha
Holcomb, Kevin
author_facet Musselman, Kelsey
Glynn, Shannon
Mosquera, Juan Miguel
Elemento, Olivier
Sboner, Andrea
Beltran, Himisha
Holcomb, Kevin
author_sort Musselman, Kelsey
collection PubMed
description Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/neu via fluorescence in situ hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response.
format Online
Article
Text
id pubmed-6411491
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-64114912019-03-22 Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma Musselman, Kelsey Glynn, Shannon Mosquera, Juan Miguel Elemento, Olivier Sboner, Andrea Beltran, Himisha Holcomb, Kevin Gynecol Oncol Rep Case Report Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/neu via fluorescence in situ hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response. Elsevier 2019-02-21 /pmc/articles/PMC6411491/ /pubmed/30906838 http://dx.doi.org/10.1016/j.gore.2019.01.013 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Musselman, Kelsey
Glynn, Shannon
Mosquera, Juan Miguel
Elemento, Olivier
Sboner, Andrea
Beltran, Himisha
Holcomb, Kevin
Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
title Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
title_full Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
title_fullStr Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
title_full_unstemmed Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
title_short Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
title_sort identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411491/
https://www.ncbi.nlm.nih.gov/pubmed/30906838
http://dx.doi.org/10.1016/j.gore.2019.01.013
work_keys_str_mv AT musselmankelsey identificationofatherapeutictargetusingmolecularsequencingfortreatmentofrecurrentuterineserousadenocarcinoma
AT glynnshannon identificationofatherapeutictargetusingmolecularsequencingfortreatmentofrecurrentuterineserousadenocarcinoma
AT mosquerajuanmiguel identificationofatherapeutictargetusingmolecularsequencingfortreatmentofrecurrentuterineserousadenocarcinoma
AT elementoolivier identificationofatherapeutictargetusingmolecularsequencingfortreatmentofrecurrentuterineserousadenocarcinoma
AT sbonerandrea identificationofatherapeutictargetusingmolecularsequencingfortreatmentofrecurrentuterineserousadenocarcinoma
AT beltranhimisha identificationofatherapeutictargetusingmolecularsequencingfortreatmentofrecurrentuterineserousadenocarcinoma
AT holcombkevin identificationofatherapeutictargetusingmolecularsequencingfortreatmentofrecurrentuterineserousadenocarcinoma

Ejemplares similares